Table 2 Multivariable analysis: time-dependent weighted average CsA levels (per 50 ng/mL) on outcome

From: Higher therapeutic CsA levels early post transplantation reduce risk of acute GVHD and improves survival

Outcomes and variables RR (95% CI) P-value
Grade II–IV acute GVHD
Weighted average CsA level 0.75 (0.62–0.90) <0.01
Donor type
 Myeloablative sibling 1.0  
 Nonmyeloablative sibling 0.74 (0.31–1.78) 0.50
 Myeloablative dUCB 1.57 (0.73–3.40) 0.25
 Nonmyeloablative dUCB 1.02 (0.49–2.16) 0.95
Chronic GVHD
Weighted average CsA level 0.90 (0.69–1.17) 0.42
Donor type
 Myeloablative sibling 1.0  
 Nonmyeloablative sibling 0.69 (0.27–1.78) 0.44
 Myeloablative dUCB 1.63 (0.61–4.35) 0.33
 Nonmyeloablative dUCB 0.35 (0.15–0.85) 0.02
Age at transplantation, years
 15–34 1.0  
 35–54 3.28 (1.31–8.23) 0.01
 55+ 6.34 (2.20–18.30) <0.01
Patient CMV serostatus
 Negative 1.0  
 Positive 2.85 (1.39–5.83) <0.01
Non-relapse mortality
Weighted average CsA level 0.75 (0.60–0.93) <0.01
Donor type
 Myeloablative sibling 1.0  
 Nonmyeloablative sibling 4.01 (0.88–18.32) 0.07
 Myeloablative dUCB 5.55 (1.30–23.73) 0.02
 Nonmyeloablative dUCB 3.16 (0.73–13.63) 0.12
Overall mortality
Weighted average CsA level 0.80 (0.67–0.95) 0.01
Donor type
 Myeloablative sibling 1.0  
 Nonmyeloablative sibling 1.89 (0.79–4.53) 0.15
 Myeloablative dUCB 1.98 (0.85–4.60) 0.11
 Nonmyeloablative dUCB 1.85 (0.83–4.12) 0.14
Patient gender
 Male 1.0  
 Female 1.49 (0.98–2.23) 0.07
  1. Abbreviations: CI=confidence interval; dUCB=double umbilical cord blood.
  2. Each 50 ng/mL increment of CsA level was tested for its impact on the outcome of interest using 70% overweighting for the pre-event samples.
  3. Statistically significant P values are in bold.